Study of Erythrocyte Parameters and Hypercoagulability in Sickle Cell Disease (SCD-TGA)
Recruiting · NCT05376046 · Observational (researchers observe without assigning treatment) · Lead sponsor: BILLOIR
View the official record on ClinicalTrials.gov →Interventions studied
Erythrocytic parameters and thrombin generation assay measurement
What this trial is about
Sickle cell disease (SCD) is an inherited haemoglobinopathy disorder caused by mutations in HBB gene with amino-acid substitution on β globin chain. The consequence is synthesis of altered haemoglobin S (HbS) which polymerises in red blood cell (RBC) at deoxygenated state. SCD is associated with chronic haemolytic anaemia, vaso-occlusive crisis (VOC) leading to frequent hospitalisation. The aim of the study was to to investigate whether a combination of routine laboratory biomarkers of haemolysis could be used to predict VOC development in confirmed SCD patients.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Sickle cell disease
Exclusion criteria
- \<18 years
- pregnancy
- Patient under protective guardianship or curatorship
Where it is running
1 location listed.
- Rouen university Hospital - Rouen, France